Optimal doses of tinzaparin to reduce both cancer-associated thrombosis and tumor growth in a mouse model of ectopic pancreatic syngeneic tumor - Aix-Marseille Université Access content directly
Journal Articles Journal of Thrombosis and Haemostasis Year : 2016

Optimal doses of tinzaparin to reduce both cancer-associated thrombosis and tumor growth in a mouse model of ectopic pancreatic syngeneic tumor

Abstract

In clinical studies, thromboprophylaxis with low-molecular-weight heparins (LMWHs) has been demonstrated to reduce the risk of venous thromboembolism and to improve outcomes in cancer patients. Moreover, preclinical models have previously suggested that LMWHs may also offer additional benefits through direct antitumor properties. However, the optimal doses of LMWHs that may prevent both cancer-related thrombosis and tumor development are yet unknown.
No file

Dates and versions

hal-01451070 , version 1 (31-01-2017)

Identifiers

Cite

Corinne Frere, Soraya Mezouar, Léa Plantureux, Lydie Crescence, Laurence Panicot-Dubois, et al.. Optimal doses of tinzaparin to reduce both cancer-associated thrombosis and tumor growth in a mouse model of ectopic pancreatic syngeneic tumor. Journal of Thrombosis and Haemostasis, 2016, 14, pp.76-76. ⟨10.1016/S0049-3848(16)30167-0⟩. ⟨hal-01451070⟩

Collections

UNIV-AMU
21 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More